Akhil Chawla

TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.

TL;DR: It is demonstrated that PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD- L1 immune checkpoint may be an effective treatment modality in patients with this disease.

TL;DR: The results show that NE uptake increases the responsiveness of breast cancer cells to adaptive immunity by broad upregulation of membrane HLA class I and support the conclusion that the innate inflammatory mediator NE enhances tumor cell recognition and increases tumor sensitivity to the host adaptive immune response.

TL;DR: Increased knowledge of tumor immunology has allowed investigators to better understand how these cells and the developing tumor interact, and this has prompted the conduct of numerous studies investigating the prognostic and predictive significance of immune infiltrates.

TL;DR: Neoadjuvant chemotherapy with FOLFIRINOX shifts the PDAC immune microenvironment towards an anti-tumorigenic state associated with improved patient survival.